Australia takes BSE (bovine spongiform encephalopathy) action
This article was originally published in Clinica
The Australian Therapeutics Goods Administration (TGA) has ruled that medical devices containing animal or human materials must be sourced from countries free of bovine spongiform encephalopathy (BSE). Failing that, their suppliers must have evidence that all necessary measures have been taken to minimise the risk of transmission. Devices already on the market that do not fulfil these requirements will be removed unless their use can be justified, says the TGA.
You may also be interested in...
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.